Alnylam announces publication of phase 1 study results for zilebesiran in the new england journal of medicine

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today that results from its phase 1 study of zilebesiran, an investigational rnai therapeutic targeting liver-expressed angiotensinogen (agt) in development for the treatment of hypertension, were published in the new england journal of medicine (nejm). the full manuscript is titled, “zilebesiran, an rna interference therapeutic agent for hypertension,” and will appe.
ALNY Ratings Summary
ALNY Quant Ranking